Scientists use electric shocks to genetically reprogramme T cells

Image
IANS New York
Last Updated : Jul 13 2018 | 6:35 PM IST

In a breakthrough, US scientists have genetically reprogrammed the human immune cells known as T cells with the help of electric shocks, instead of the traditional method of using viruses to insert DNA.

The new method, using CRISPR gene-editing technology, described in the journal Nature, offers a robust molecular "cut and paste" system to rewrite genome sequences in human T cells.

It relies on electroporation, a process in which an electrical field is applied to cells to make their membranes temporarily more permeable.

The researchers from the University of California-San Francisco (UCSF), found that when certain quantities of T cells, DNA, and the CRISPR "scissors" are mixed together and then exposed to an appropriate electrical field, the T cells will take in these elements and integrate specified genetic sequences precisely at the site of a CRISPR-programmed cut in the genome.

"This is a rapid, flexible method that can be used to alter, enhance, and reprogramme T cells so we can give them the specificity we want to destroy cancer, recognize infections, or tamp down the excessive immune response seen in autoimmune disease," said Alex Marson, Associate Professor at the UCSF.

"Now we're off to the races on all these fronts," he added.

Besides the new technique's speed and ease of use, the approach makes it possible to insert substantial stretches of DNA into T cells, which can endow the cells with powerful new properties as well as pave the way to more precise therapies that could be far more effective in tackling cancer or some other T cell targeted disease.

The team used the novel approach to repair a disease-causing genetic mutation in T cells from children with a rare genetic form of autoimmunity, and also created customized T cells to seek out and kill human melanoma cells.

They also used it to create a new T cell therapy for melanoma, successfully testing it in mice. Now they are focusing to experiment it in humans.

--IANS

rt/mag/bg

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 13 2018 | 6:26 PM IST

Next Story